NDAORAL-21TABLET
Approved
Nov 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
TRIPHASIL-21 (ethinyl estradiol; levonorgestrel) by Pfizer. Approved for pregnancy. First approved in 1984.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRIPHASIL-21 is a triphasic oral contraceptive combining ethinyl estradiol and levonorgestrel in a 21-day tablet regimen. It prevents pregnancy through hormonal suppression of ovulation and alteration of cervical mucus. The product has been a cornerstone of hormonal contraception since its 1984 approval.
LOE Approaching
Product is in late-stage lifecycle with significant generic/competitive pressure (30% competitive intensity), indicating reduced commercial team investment and shifting focus to legacy management.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (1)
Career Relevance
Working on TRIPHASIL-21 offers limited growth opportunity but strong defensive strategy experience in a mature, high-competition environment. Career trajectory favors managed care, generics strategy, and portfolio rationalization expertise rather than innovation or field expansion roles.
Brand Manager
Worked on TRIPHASIL-21 at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.